HUE048855T2 - RSV-re specifikus ellenanyagok és azok funkcionális részei - Google Patents

RSV-re specifikus ellenanyagok és azok funkcionális részei

Info

Publication number
HUE048855T2
HUE048855T2 HUE15737068A HUE15737068A HUE048855T2 HU E048855 T2 HUE048855 T2 HU E048855T2 HU E15737068 A HUE15737068 A HU E15737068A HU E15737068 A HUE15737068 A HU E15737068A HU E048855 T2 HUE048855 T2 HU E048855T2
Authority
HU
Hungary
Prior art keywords
rsv
antibodies specific
functional parts
functional
parts
Prior art date
Application number
HUE15737068A
Other languages
English (en)
Hungarian (hu)
Inventor
Nancy Ulbrandt
Nicole Kallewaard-Lelay
Andy Q Yuan
Bettina Richter
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HUE048855T2 publication Critical patent/HUE048855T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE15737068A 2014-01-15 2015-01-14 RSV-re specifikus ellenanyagok és azok funkcionális részei HUE048855T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15

Publications (1)

Publication Number Publication Date
HUE048855T2 true HUE048855T2 (hu) 2020-08-28

Family

ID=53543612

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15737068A HUE048855T2 (hu) 2014-01-15 2015-01-14 RSV-re specifikus ellenanyagok és azok funkcionális részei
HUS2300019C HUS2300019I1 (hu) 2014-01-15 2023-05-02 RSV-re specifikus ellenanyagok és azok funkcionális részei

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2300019C HUS2300019I1 (hu) 2014-01-15 2023-05-02 RSV-re specifikus ellenanyagok és azok funkcionális részei

Country Status (26)

Country Link
US (6) US20160340414A1 (enExample)
EP (3) EP3094353B1 (enExample)
JP (3) JP6836398B2 (enExample)
KR (1) KR102188437B1 (enExample)
CN (2) CN116355080A (enExample)
AU (4) AU2015206570A1 (enExample)
CA (1) CA2933200C (enExample)
CY (2) CY1123425T1 (enExample)
DK (1) DK3094353T3 (enExample)
ES (1) ES2795727T3 (enExample)
FI (1) FIC20230016I1 (enExample)
FR (1) FR23C1016I2 (enExample)
HR (1) HRP20200607T1 (enExample)
HU (2) HUE048855T2 (enExample)
LT (2) LT3094353T (enExample)
LU (1) LUC00305I2 (enExample)
MX (1) MX374517B (enExample)
NL (1) NL301228I2 (enExample)
NO (1) NO2023016I1 (enExample)
PL (1) PL3094353T3 (enExample)
PT (1) PT3094353T (enExample)
RS (1) RS60387B1 (enExample)
SI (1) SI3094353T1 (enExample)
SM (1) SMT202000282T1 (enExample)
TW (1) TWI705974B (enExample)
WO (1) WO2015108967A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
WO2018075954A2 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20200140799A (ko) * 2018-01-31 2020-12-16 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
KR20240055097A (ko) 2021-09-13 2024-04-26 메디뮨 리미티드 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방
CN116987183B (zh) * 2022-07-22 2024-10-15 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
CN122057014A (zh) * 2024-11-08 2026-05-19 珠海泰诺麦博制药股份有限公司 一种抗rsv抗体在预防和治疗rsv中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
CA2678628A1 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
ES2579231T3 (es) 2008-01-15 2016-08-08 Abbvie Inc Vectores de expresión de mamíferos mejorados y usos de los mismos
WO2011008093A1 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
MX2012001882A (es) * 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011043643A1 (en) * 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
EP2591000B1 (en) * 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
AU2013234046B2 (en) * 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
US20150158942A1 (en) * 2012-05-22 2015-06-11 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Also Published As

Publication number Publication date
WO2015108967A8 (en) 2015-10-01
LT3094353T (lt) 2020-08-10
NL301228I2 (nl) 2023-09-13
BR112016015044A2 (pt) 2017-09-19
CA2933200A1 (en) 2015-07-23
MX2016008639A (es) 2017-02-15
BR112016015044A8 (pt) 2023-04-11
US20250179153A1 (en) 2025-06-05
US12173050B2 (en) 2024-12-24
EP4353316A2 (en) 2024-04-17
CY2023011I1 (el) 2023-11-15
DK3094353T3 (da) 2020-06-02
AU2025201056A1 (en) 2025-03-06
SI3094353T1 (sl) 2020-07-31
KR102188437B1 (ko) 2020-12-08
AU2021204339A1 (en) 2021-07-22
CY2023011I2 (el) 2023-11-15
US20230365660A1 (en) 2023-11-16
AU2015206570A1 (en) 2016-07-14
JP2025063143A (ja) 2025-04-15
AU2020203831A1 (en) 2020-07-02
JP2023052693A (ja) 2023-04-11
EP3741390A1 (en) 2020-11-25
EP3094353B1 (en) 2020-04-01
WO2015108967A2 (en) 2015-07-23
RU2016133247A (ru) 2018-02-20
ES2795727T3 (es) 2020-11-24
JP2020103293A (ja) 2020-07-09
CA2933200C (en) 2025-05-06
LUC00305I2 (enExample) 2025-09-22
EP4353316A3 (en) 2024-08-21
HUS2300019I1 (hu) 2023-05-28
LTPA2023514I1 (enExample) 2023-05-25
RS60387B1 (sr) 2020-07-31
WO2015108967A3 (en) 2015-09-03
US11661449B2 (en) 2023-05-30
JP6836398B2 (ja) 2021-03-03
FIC20230016I1 (fi) 2023-04-26
PL3094353T3 (pl) 2020-09-07
EP3094353A2 (en) 2016-11-23
FR23C1016I1 (fr) 2023-06-23
EP3094353A4 (en) 2017-09-06
NL301228I1 (enExample) 2023-05-03
NO2023016I1 (no) 2023-04-25
US20220098285A1 (en) 2022-03-31
US20160340414A1 (en) 2016-11-24
TWI705974B (zh) 2020-10-01
PT3094353T (pt) 2020-06-08
CY1123425T1 (el) 2021-12-31
MX374517B (es) 2025-03-06
LTC3094353I2 (enExample) 2025-07-10
US11186628B2 (en) 2021-11-30
US20190106482A1 (en) 2019-04-11
CN105916520A (zh) 2016-08-31
KR20160104018A (ko) 2016-09-02
TW201612191A (en) 2016-04-01
HRP20200607T1 (hr) 2020-07-10
US10689437B2 (en) 2020-06-23
US20200331989A1 (en) 2020-10-22
CN116355080A (zh) 2023-06-30
JP2017504321A (ja) 2017-02-09
RU2016133247A3 (enExample) 2019-01-16
HK1225992A1 (en) 2017-09-22
FR23C1016I2 (fr) 2026-05-29
AU2021204339B2 (en) 2024-11-14
SMT202000282T1 (it) 2020-07-08
ES2795727T9 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
IL304772A (en) Antibodies, uses and methods
IL283965A (en) Antibodies against cd73 and uses thereof
IL251963A0 (en) Anti-pd-1 antibodies
HUE045216T2 (hu) Anti-CD79B antitestek és alkalmazási eljárások
HUE052771T2 (hu) C10orf54 elleni antitestek és alkalmazásuk
HUE060165T2 (hu) PD-1 elleni ellenanyagok és alkalmazásukra szolgáló eljárások
DK3344654T3 (da) Anti-lag-3-antistoffer
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
EP3319984C0 (en) TAU LINKING ANTIBODIES
HUS2300019I1 (hu) RSV-re specifikus ellenanyagok és azok funkcionális részei
HUE053857T2 (hu) Anti-GITR antitestek és eljárások azok elõállítására
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
LT3215532T (lt) Anti-tim3 antikūnai ir jų naudojimo būdai
HUE043363T2 (hu) Antitest molekulák PD-1-hez és azok felhasználásai
HUE053641T2 (hu) Anti-LAG3 antitestek és antigénkötõ fragmentumok
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
EP3319983C0 (en) TAU LINKING ANTIBODIES
HUE060878T2 (hu) Anti-transztiretin antitestek
IL291164A (en) Anti-nme antibody
DK3250593T3 (da) Anti-transthyretin-antistoffer
IL282201B (en) Anti-tenascin c antibodies and uses thereof
LT3092003T (lt) Naujas anti-netrino-1 antikūnas
DK3452515T3 (da) Her-2-bindende antistoffer
EP3160502B1 (en) BI-SPECIFIC ANTIBODIES ANTI-IL4-IL13